# Madrigal Pharmaceuticals, Inc. clinical trials: 21 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 21 trials with Madrigal Pharmaceuticals, Inc. as lead sponsor, 5 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Madrigal Pharmaceuticals, Inc.: 21 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/madrigal-pharmaceuticals-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 21
- Recruiting or not yet: 5
- Read on: November 19, 2026

## Trials

The 21 newest of 21, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 29, 2026 | NCT07848191 | Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis | Madrigal Pharmaceuticals, Inc. | Phase 4 | Recruiting | MASH - Metabolic Dysfunction-Associated Steatohepatitis | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07848191) |
| September 21, 2026 | NCT07830758 | Resmetirom in Patients With MASH and HFpEF | Madrigal Pharmaceuticals, Inc. | Phase 1 | Recruiting | MASH - Metabolic Dysfunction-Associated Steatohepatitis, Heart Failure With Preserved Ejection Fraction (HFPEF) | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07830758) |
| August 13, 2026 | NCT07763015 | Study of Resmetirom in Children and Adolescents With MASH | Madrigal Pharmaceuticals, Inc. | Phase 2 | Recruiting | MASH, MASH - Metabolic Dysfunction-Associated Steatohepatitis | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07763015) |
| April 21, 2026 | NCT07541469 | Rezdiffra Pregnancy and Lactation Registry | Madrigal Pharmaceuticals, Inc. | Observational | Recruiting | MASH - Metabolic Dysfunction-Associated Steatohepatitis | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07541469) |
| January 13, 2026 | NCT07335601 | Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH | Madrigal Pharmaceuticals, Inc. | Phase 2 | Recruiting | MASH - Metabolic Dysfunction-Associated Steatohepatitis | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07335601) |
| May 3, 2024 | NCT06397872 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With... | Madrigal Pharmaceuticals, Inc. | Phase 1 | Completed | Renal Impairment | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06397872) |
| August 15, 2022 | NCT05500222 | A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis... | Madrigal Pharmaceuticals, Inc. | Phase 3 | Active not recruiting | NASH, Cirrhosis, Liver | 845 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05500222) |
| July 6, 2021 | NCT04951219 | A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD)... | Madrigal Pharmaceuticals, Inc. | Phase 3 | Active not recruiting | Non-Alcoholic Fatty Liver Disease | 810 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04951219) |
| December 17, 2020 | NCT04671069 | Drug Interaction Study of MGL-3196 With Clopidogrel | Madrigal Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04671069) |
| December 17, 2020 | NCT04671056 | Drug Interaction Study of MGL-3196 With Pioglitazone | Madrigal Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04671056) |
| November 25, 2020 | NCT04643795 | Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying... | Madrigal Pharmaceuticals, Inc. | Phase 1 | Completed | Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver | 87 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04643795) |
| December 13, 2019 | NCT04197479 | A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients | Madrigal Pharmaceuticals, Inc. | Phase 3 | Completed | Non-Alcoholic Fatty Liver Disease | 1,343 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04197479) |
| April 3, 2019 | NCT03900429 | A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis | Madrigal Pharmaceuticals, Inc. | Phase 3 | Active not recruiting | NASH - Nonalcoholic Steatohepatitis | 1,759 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03900429) |
| January 29, 2018 | NCT03413124 | Bioavailability Study of MGL-3196 Tablets Compared to Capsules | Madrigal Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03413124) |
| July 18, 2017 | NCT03220165 | Radiolabeled Study to Determine the Mass Balance of \[14C\] MGL-3196 | Madrigal Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03220165) |
| January 31, 2017 | NCT03038022 | Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) | Madrigal Pharmaceuticals, Inc. | Phase 2 | Completed | Heterozygous Familial Hypercholesterolemia | 116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03038022) |
| September 23, 2016 | NCT02912260 | Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH) | Madrigal Pharmaceuticals, Inc. | Phase 2 | Completed | Non-alcoholic Steatohepatitis | 125 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02912260) |
| April 25, 2016 | NCT02749578 | Drug Interaction Study of MGL-3196 With Atorvastatin | Madrigal Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02749578) |
| September 7, 2015 | NCT02542969 | Drug Interaction Study of MGL-3196 With Rosuvastatin and Simvastatin | Madrigal Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02542969) |
| January 27, 2012 | NCT01519531 | Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy Subjects | Madrigal Pharmaceuticals, Inc. | Phase 1 | Completed | Drug Safety | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01519531) |
| June 7, 2011 | NCT01367873 | Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects | Madrigal Pharmaceuticals, Inc. | Phase 1 | Completed | Drug Safety | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01367873) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 11 |
| Phase 2 | 4 |
| Phase 3 | 4 |
| Phase 4 | 1 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 13 |
| Recruiting | 5 |
| Active not recruiting | 3 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Non-alcoholic Fatty Liver Disease | 5 |
| Fibrosis | 4 |
| Liver Cirrhosis | 2 |
| Hyperlipidemias | 2 |
| Thyroid Hormone Resistance Syndrome | 2 |
| Dyslipidemias | 2 |
| Liver Diseases | 1 |
| Renal Insufficiency | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Media agencies in the United States](https://specstream.ai/data/businesses/media-agencies/united-states)
- [Wholesalers in the United States](https://specstream.ai/data/businesses/wholesalers/united-states)
- [Filipino restaurants in the United States](https://specstream.ai/data/businesses/filipino-restaurants/united-states)
- [Publishers in the United States](https://specstream.ai/data/businesses/publishers/united-states)
- [Burger restaurants in the United States](https://specstream.ai/data/businesses/burger-restaurants/united-states)
